Invokana or Canagliflozin Tablets are a diabetes medication that was intended to lower blood sugar (A1C) for adults suffering from Type 2 diabetes.  The manufacturers suggest that taking INVOKANA along with diet and exercise can significantly lower A1C in diabetes patients.  The tablets are manufactured by Janssen Pharmaceuticals. 


It is believed that nearly 30 million people in the United States suffer from diabetes with the majority suffering from Type 2 diabetes.  Diabetes, according to the American Diabetes Association is the 7th leading cause of death in the United States.  Drug companies have tried to develop miracle drugs to help combat this deadly disease.  INVOKANA was introduced on the market to help lower a Type 2 diabetic’s blood sugar.


It has been discovered that Invokana can have serious side effects including severe heart issues, kidney disease and ketoacidosis.  Janssen Pharmaceuticals failed to warn the public including physicians and patients prescribed INVOKANA of the increased risks.  Janssen has since issued an express warning of the potential for acute kidney injuries linked to use of Invokana.  While there has not been a direct recall of the drug, the US Food and Drug Administration has now issued multiple safety warnings regarding Invokana.  The FDA now requires a new safety labeling on the drug regarding the potential for acute kidney injury and impairment in renal function.   


Invokana has also been found to result in an increase in bone fractures, serious urinary tract infections, hypotension and acute kidney injury.  During clinical trials there was an increase in leg and foot amputations for patients prescribed the medicine.    


If you or someone you know has experienced any adverse reactions such as vomiting, abdominal pain, nausea, tiredness, trouble breathing you may be entitled to compensation as a result of a defective or dangerous drug.  These are signs of ketoacidosis or increased ketones in your blood or urine and can lead to death. 


INVOKANA was introduced to the market and approved by the US Food and Drug Administration in March of 2013.  The FDA received 101 confirmable reports of acute kidney injury from March 2013 until October 2015.  Due to the known link between the drug and increased potential for acute kidney injury the FDA required the manufacturer to add safety warnings regarding this dangerous side effect.  The FDA followed up with additional requirements regarding the potential for ketoacidosis and most recently that clinical trials show an increased potential for leg or foot amputation.




Call today toll free to receive a free case evaluation.  We care about you, what happened and how it happened.  We want to hear the full story.  No detail is too small.  Call today and speak to an actual personal injury or mass tort lawyer.  We are litigators and will take your case to trial to get you the compensation you deserve.  Do not wait until it is too late.